Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin

Clinical and Experimental Immunology

Volumn 155, Issue 1, 2009, Pages 28-34

  Nicoletti, F ^a   Lamenta, C ^b   Donati, S ^b   Spada, M ^b   Ranazzi, A ^b   Cacopardo, B ^c   Mangano, K ^a   Belardelli, F ^b   Perno, C ^d   Aquaro, S ^e  

^a UNIVERSITY OF CATANIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Medical Specialties Unit of Infectious Diseases   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF CALABRIA   (Italy)

Author keywords

CD4 CD8; HIV; Hu PBL SCID; Immunotherapy; RAPA

Indexed keywords

RAPAMYCIN; VIRUS DNA; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA DETERMINATION; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE; LYMPH NODE; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROVIRUS; SEVERE COMBINED IMMUNODEFICIENCY; SPLEEN CELL; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPH NODES; MICE; MICE, SCID; MODELS, ANIMAL; PERITONEUM; RNA, VIRAL; SIROLIMUS; SPLEEN;

EID: 57449093795     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03780.x     Document Type: Article

References (33)

1. Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK, Watanabe MA. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection. Curr Med Chem 2007 14 : 1325 34.
2. Reynes J, Portales P, Segondy M et al. CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 2001 15 : 1627 34.
3. Reynes J, Portales P, Segondy M et al. CD4 cell surface CCR5 density as a determining factor of viral load in HIV-infected individuals. J Infect Dis 2000 181 : 927 32.
4. Repik A, Richards KH, Clapham PR. The promise of CCR5 antagonists as new therapies for HIV-1. Curr Opin Invest Drugs 2007 8 : 130 9.
5. Fätkenheuer G, Pozniak AL, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005 11 : 1170 2.
6. Gulick RM, Su Z, Flexner C et al. AIDS Clinical Trials Group 5211 Team. J Infect Dis 2007 196 : 304 12.
7. Albers MW, Brown EJ, Tanaka A, Williams RT, Hall FL, Schreiber SL. An FKBP-rapamycin-sensitive, cyclin-dependent kinase activity that correlates with the FKBP-rapamycin-induced G1 arrest point in MG-63 cells. Ann NY Acad Sci 1993 696 : 54 62.
8. Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem 1993 268 : 22737 45.
9. Dittmer DP, Krown SE. Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 2007 19 : 425 27.
10. Jacquenet S, Ropers D, Bilodeau PS et al. Conserved stem-loop structures in the HIV-1 RNA region containing the A3 3′ splice site and its cis-regulatory element: possible involvement in RNA splicing. Nucleic Acids Res 2001 29 : 464 78.
11. Si Z, Amendt BA, Stoltzfus CM. Splicing efficiency of human immunodeficiency virus type 1 tat RNA is determined by both a suboptimal 3′ splice site and a 10 nucleotide exon splicing silencer element located within tat exon 2. Nucleic Acids Res 1997 25 : 861 7.
12. Staffa A, Cochrane A. The tat/rev intron of human immunodeficiency virus type 1 is inefficiently spliced because of suboptimal signals in the 3′ splice site. J Virol 1994 68 : 3071 9.
13. Tanga TÃ, Kjems J. SF2/ASF binds to a splicing enhancer in the third HIV-1 tat exon and stimulates U2AF binding independently of the RS domain. J Mol Biol 2001 312 : 649 62.
14. Roy S, Paquette JS, Fortin JF, Tremblay MJ. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 2002 46 : 3447 55.
15. Oswald-Richter K, Grill SM, Leelawong M, Unutmaz D. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. Eur J Immunol 2004 34 : 1705 14.
16. Heredia A, Amoroso A, Davis C et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress r5 strains of HIV-1. Proc Natl Acad Sci USA 2003 100 : 10411 16.
17. Gilliam BL, Heredia A, Devico A et al. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS 2007 21 : 2108 10.
18. Rizza P, Santini SM, Logozzi M et al. T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells. J Virol 1996 70 : 7958 64.
19. Santini SM, Lapenta C, Logozzi M et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000 191 : 1777 88.
20. Garaci E, Aquaro S, Lapenta C et al. Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice. Proc Natl Acad Sci USA 2003 22 : 8927 32.
21. Lapenta C, Santini SM, Logozzi M et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 2003 198 : 361 7.
22. Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci 2005 77 : 1711 22.
23. Del Real G, Jiménez-Baranda S, Mira E et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004 200 : 541 7.
24. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992 89 : 174 8.
25. Argyropoulos C, Mouraki A. Immunosuppressive drugs in HIV disease. Curr Top Med Chem 2006 6 : 1769 89.
26. Kelly LM, Lisziewitz J, Lori F. Virostatics as a potential new class of HIV drugs. Curr Pharm Des 2004 10 : 4103 20.
27. Damoiseaux JG, Beijleveld LJ, Schuurman HJ, van Breda Vriesman PJ. Effect of in vivo rapamycin treatment on de novo T-cell development in relation to induction of autoimmune-like immunopathology in the rat. Transplantation 1996 62 : 994 1001.
28. DeLuca C, Kwon H, Lin R, Wainberg M, Hiscott J. NF-kappaB activation and HIV-1 induced apoptosis. Cytokine Growth Factor Rev 1999 10 : 235 53.
29. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001 12 : 133 50.
30. Puzik A, Schultz C, Iblher P, Müller-Steinhardt M, Härtel C. Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells. Acta Paediatr 2007 96 : 1483 9.
31. Giordano A, Avellino R, Ferraro P, Romano S, Corcione N, Romano MF. Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis. Am J Physiol Heart Circ Physiol 2006 290 : H2459 65.
32. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008 22 : 1490 500.
33. Heredia A, Gilliam B, Latinovic O et al. Rapamycin reduces CCR5 density levels on CD4 T cells and this effect results in potentiation of Enfuvirtide (T-20) against R5 HIV-1 in vitro. Antimicrob Agents Chemother 2007 51 : 2489 96.